Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue of Rs 3,623 crore. This represented a flat year-on-year change, with operational revenue at Rs 3,590 crore, showing a 4% increase compared to the previous year. The company emphasized an 8% growth in operating revenue when adjusted […]
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. The deal, which was announced in February 2022, closed after Biocon Biologics and Viatris secured all the required approvals from major global regulators such as the US Federal Trade Commission […]
Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited (SILS) at an enterprise value of around $4.9 billion. Serum Institute Life Sciences is a subsidiary of Serum Institute of India. The deal gives Biocon Biologics access to 100 million […]
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing an antibody treatment based on ADG20 for India and certain emerging markets. ADG20 is a novel monoclonal antibody that targets the spike protein of SARS-CoV-2 and related coronaviruses. It is […]